Physician profile
John Tellers
NPI 1881634889
$582.85
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $122.31 | 2019 | |
| Livanova USA, INC. | $96.81 | 2019 | |
| Amgen INC. | $66.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $56.07 | 2019 | |
| Ucb, INC. | $37.77 | 2019 | |
| Acorda Therapeutics, INC | $36.14 | 2019 | |
| Amneal Pharmaceuticals LLC | $35.99 | 2019 | |
| Supernus Pharmaceuticals, INC. | $32.47 | 2019 | |
| Greenwich Biosciences, INC. | $22.89 | 2019 | |
| Biogen, INC. | $21.88 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.94 | 2019 | |
| Genzyme Corporation | $14.89 | 2019 | |
| Neurocrine Biosciences, INC. | $12.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.